This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Press, O. W. Articles by Fisher, R. I. Search for Related Content PubMed PubMed Citation Articles by Press, O. W. Articles by Fisher, R. I. Social Bookmarking                            What's this?

Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin’s Disease

From the Fred Hutchinson Cancer Research Center; University of Washington; and Southwest Oncology Group Statistical Center, Seattle, WA; University of Michigan Medical Center, Ann Arbor, MI; University of Arizona Cancer Center, Tucson, AZ; Washington University Jewish Hospital, St Louis, MO; Loyola University, Stritch School of Medicine, Maywood, IL; and University of Minnesota, Minneapolis, MN.

Address reprint requests to Southwest Oncology Group 9133, Operations Office, 14980 Omicron Dr, San Antonio, TX 78245-3217.

PURPOSE: The management of early-stage Hodgkin’s disease in the United States is controversial. To evaluate whether staging laparotomy could be safely avoided in early-stage Hodgkin’s disease and whether chemotherapy should be a part of the treatment of nonlaparotomy staged patients, a phase III intergroup trial was performed.

PATIENTS AND METHODS: Three hundred forty-eight patients with clinical stage IA to IIA supradiaphragmatic Hodgkin’s disease were randomized without staging laparotomy to treatment with either subtotal lymphoid irradiation (STLI) or combined-modality therapy (CMT) consisting of three cycles of doxorubicin and vinblastine followed by STLI.

RESULTS: The study was closed at the second, planned, interim analysis because of a markedly superior failure-free survival (FFS) rate for patients on the CMT arm (94%) compared with the STLI arm (81%). With a median follow-up of 3.3 years, 10 patients have experienced relapse or died on the chemoradiotherapy arm, compared with 34 on the radiotherapy arm (P < .001). Few deaths have occurred on either arm (three deaths on CMT and seven deaths on STLI). Treatment was well tolerated, with only one death on each arm attributed to treatment.

CONCLUSION: These results demonstrate that it is possible to obtain a high FFS rate in a large group of stage IA to IIA patients without performing staging laparotomy and that three cycles of chemotherapy plus STLI provide a superior FFS compared with STLI alone. Extended follow-up is necessary to assess freedom from second relapse, overall survival, late toxicities, patterns of treatment failure, and quality of life.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. L. Korn, B. Freidlin, and M. Mooney Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005 J. Clin. Oncol., April 1, 2009; 27(10): 1712 - 1721. [Abstract] [Full Text] [PDF]

				E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up Haematologica, April 1, 2009; 94(4): 550 - 565. [Abstract] [Full Text] [PDF]

				F. Trotta, G. Apolone, S. Garattini, and G. Tafuri Stopping a trial early in oncology: for patients or for industry? Ann. Onc., July 1, 2008; 19(7): 1347 - 1353. [Abstract] [Full Text] [PDF]

				P. A. Ganz and C. C. Gotay Use of Patient-Reported Outcomes in Phase III Cancer Treatment Trials: Lessons Learned and Future Directions J. Clin. Oncol., November 10, 2007; 25(32): 5063 - 5069. [Abstract] [Full Text] [PDF]

				C. Ferme, H. Eghbali, J. H. Meerwaldt, C. Rieux, J. Bosq, F. Berger, T. Girinsky, P. Brice, M. B. van't Veer, J. A. Walewski, et al. Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease N. Engl. J. Med., November 8, 2007; 357(19): 1916 - 1927. [Abstract] [Full Text] [PDF]

				A. Engert, J. Franklin, H. T. Eich, C. Brillant, S. Sehlen, C. Cartoni, R. Herrmann, M. Pfreundschuh, M. Sieber, H. Tesch, et al. Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial J. Clin. Oncol., August 10, 2007; 25(23): 3495 - 3502. [Abstract] [Full Text] [PDF]

				M. Sieniawski, J. Franklin, L. Nogova, J.-P. Glossmann, T. Schober, H. Nisters-Backes, V. Diehl, and A. Josting Outcome of Patients Experiencing Progression or Relapse After Primary Treatment With Two Cycles of Chemotherapy and Radiotherapy for Early-Stage Favorable Hodgkin's Lymphoma J. Clin. Oncol., May 20, 2007; 25(15): 2000 - 2005. [Abstract] [Full Text] [PDF]

				J Franklin, A Pluetschow, M Paus, L Specht, A-P Anselmo, A Aviles, G Biti, T Bogatyreva, G Bonadonna, C Brillant, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials Ann. Onc., December 1, 2006; 17(12): 1749 - 1760. [Abstract] [Full Text] [PDF]

				A. Ng, S Li, D Neuberg, D. Fisher, C McMillan, B Silver, K. Marcus, M. Stevenson, and P. Mauch Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease Ann. Onc., November 1, 2006; 17(11): 1693 - 1697. [Abstract] [Full Text] [PDF]

				E. Brusamolino, A. Baio, E. Orlandi, L. Arcaini, F. Passamonti, V. Griva, W. Casagrande, C. Pascutto, P. Franchini, and M. Lazzarino Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up. Clin. Cancer Res., November 1, 2006; 12(21): 6487 - 6493. [Abstract] [Full Text] [PDF]

				J. Yahalom Don't Throw Out the Baby With the Bathwater: On Optimizing Cure and Reducing Toxicity in Hodgkin's Lymphoma J. Clin. Oncol., February 1, 2006; 24(4): 544 - 548. [Full Text] [PDF]

				M. LeBlanc, J. Moon, and C. Kooperberg Extreme regression Biostat., January 1, 2006; 7(1): 71 - 84. [Abstract] [Full Text] [PDF]

				M. K. Gospodarowicz and R. M. Meyer The Management of Patients with Limited-Stage Classical Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 253 - 258. [Abstract] [Full Text] [PDF]

				Additional Information JAMA, November 2, 2005; 294(17): E1 - E3. [Full Text] [PDF]

				R. M. Meyer, M. K. Gospodarowicz, J. M. Connors, R. G. Pearcey, A. Bezjak, W. A. Wells, B. F. Burns, J. N. Winter, S. J. Horning, A. R. Dar, et al. Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin's Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group J. Clin. Oncol., July 20, 2005; 23(21): 4634 - 4642. [Abstract] [Full Text] [PDF]

				G. P. Canellos Chemotherapy Alone for Early Hodgkin's Lymphoma: An Emerging Option J. Clin. Oncol., July 20, 2005; 23(21): 4574 - 4576. [Full Text] [PDF]

				P. Feugier, E. Labouyrie, M. Djeridane, A. Jenabian, V. Dubruille, C. Berthou, C. Ghandour, B. Desablens, Y. Chait, P. Casassus, et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation Blood, November 1, 2004; 104(9): 2675 - 2681. [Abstract] [Full Text] [PDF]

				M. Bendandi, S. A. Pileri, and P. L. Zinzani Challenging paradigms in lymphoma treatment Ann. Onc., May 1, 2004; 15(5): 703 - 711. [Full Text] [PDF]

				A. K. Ng, S. Li, D. Neuberg, B. Silver, J. Weeks, and P. Mauch Factors influencing treatment recommendations in early-stage Hodgkin's disease: a survey of physicians Ann. Onc., February 1, 2004; 15(2): 261 - 269. [Abstract] [Full Text] [PDF]

				A. K. Ng, S. Li, D. Neuberg, B. Silver, M. A. Stevenson, D. C. Fisher, and P. M. Mauch Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease Ann. Onc., February 1, 2004; 15(2): 270 - 275. [Abstract] [Full Text] [PDF]

				R. M. Meyer, R. F. Ambinder, and S. Stroobants Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice Hematology, January 1, 2004; 2004(1): 184 - 202. [Abstract] [Full Text] [PDF]

				C. l. Maignan, B. Desablens, V. Delwail, M. Dib, C. Berthou, M. Vigier, C. Ghandour, S. Atmani, P. Casassus, H. Maisonneuve, et al. Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial Blood, January 1, 2004; 103(1): 58 - 66. [Abstract] [Full Text] [PDF]

				P. A. Ganz, C. M. Moinpour, D. K. Pauler, A. B. Kornblith, E. R. Gaynor, S. P. Balcerzak, G. S. Gatti, H. P. Erba, S. McCoy, O. W. Press, et al. Health Status and Quality of Life in Patients With Early-Stage Hodgkin's Disease Treated on Southwest Oncology Group Study 9133 J. Clin. Oncol., September 15, 2003; 21(18): 3512 - 3519. [Abstract] [Full Text] [PDF]

				V. Diehl, H. Stein, M. Hummel, R. Zollinger, and J. M. Connors Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease Hematology, January 1, 2003; 2003(1): 225 - 247. [Abstract] [Full Text] [PDF]

				L. R. Prosnitz Reducing Treatment-Related Morbidity and Mortality in Early-Stage Hodgkin's Disease and Why the Recent Southwest Oncology Group Trial Is Not the Way to Go J. Clin. Oncol., May 1, 2002; 20(9): 2225 - 2228. [Full Text] [PDF]